Q-omics provides the consensus-scored ZBTB12BP profile across patient tissues and cancer cell-line models. ZBTB12BP expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, ZBTB12BP is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, ZBTB12BP RNA expression shows 19,233 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CESC, COAD, and THYM as cancer lineages where ZBTB12BP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZBTB12BP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZBTB12BP survival associations across molecular data types. ZBTB12BP RNA expression shows survival associations in the most cancer types (27). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZBTB12BP RNA expression–survival associations across cancer types. High ZBTB12BP expression shows unfavorable associations in CESC, UVM, KIRC, LGG and THCA, but favorable associations in UCS. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify CESC as the clearest survival context for ZBTB12BP RNA expression.
This table summarizes ZBTB12BP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ZBTB12BP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZBTB12BP shows higher tumor expression in COAD, HNSC, KICH, KIRC, STAD and BLCA. The COAD box plot shows higher ZBTB12BP RNA expression in tumor versus normal tissue (log2 FC = +0.336, t-test p < 0.001).
This table shows molecular features associated with ZBTB12BP in patient tissues and cancer cell lines. In patient samples, ZBTB12BP shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
